

A new report from PharmaDeals®

Trends in Pharmaceutical Deal Making

An Analysis of Valuations, Deal Structures and Deal Types

Edited by
Adrian Dawkes
and **Jansen Jacob**
with consultants of PharmaVentures

Contents

Introduction	7	Evaluation Agreements	40
1		5.1 Rationale	40
Trends in Deal Making	9	5.2 PharmaDeals Analysis	41
1.1 Recent Trends	9	5.3 Case Study: Ambrilia and ZBx	44
1.2 Deal Making by the Top 25 Pharmaceutical Companies	11	6	
1.3 Biotechnology Company Perspective	14	Technology Access Agreements	45
1.4 Sector Trends	15	6.1 Rationale	45
1.5 Changing Deals for Difficult Economic Times ...	17	6.2 PharmaDeals Analysis	46
2		6.3 Case Study: Alnylam and Takeda	49
Valuation Methods	19	7	
2.1 Combining Methods	19	Co-Marketing & Co-Promotion Agreements	51
2.2 Why use eNPV and Benchmarking?	20	7.1 Rationale	51
2.2.1 Benchmarking	21	7.2 PharmaDeals Analysis	52
2.2.2 Expected Net Present Value	21	7.3 Key Issues	55
2.2.3 Decision Trees	22	7.4 Case Study: Astellas and CoMentis	56
2.2.4 Sensitivity Analysis	23	8	
2.2.5 Value Sharing	23	Marketing Agreements	58
3		8.1 Rationale	58
Simple Licensing Agreements	25	8.2 PharmaDeals Analysis	59
3.1 Simple License Definition	25	8.3 Case Study: Alkermes and Cilag	62
3.1.1 Rationale	25	9	
3.1.2 PharmaDeals Analysis	26	Product Sale and Purchase Agreements ...	64
3.2 Key Issues	30	9.1 Single Product Sale/Purchase	64
3.2.1 Simple License	30	9.1.1 Rationale	64
3.3 Licensing Case Study: Roche	32	9.2 PharmaDeals Analysis	65
3.4 Simple Licensing Case Study: S*Bio and Oynx	34	9.3 Case Study: PDL BioPharma and EKR	69
4			
Collaborative R&D Agreements	35		
4.1 Rationale	35		
4.2 PharmaDeals Analysis	36		
4.3 Case Study: Astex and Janssen	39		

10

Option Agreements	71
10.1 Option to Purchase.....	71
10.1.1 Rationale.....	71
10.2 PharmaDeals Analysis.....	72
10.3 Option to License	75
10.3.1 Rationale.....	75
10.4 PharmaDeals Analysis.....	76
10.5 Key Issues.....	79
10.5.1 License with Option to Purchase	80
10.6 Valuation Methods.....	80
10.6.1 License with Option to Purchase	81
10.7 Case Study: Ribomic and Archemix.....	81

11

Equity Investments	83
---------------------------------	----

12

Alternate Deal Structures	87
12.1 Drug Royalty Companies	87
12.2 Risk Sharing Agreements with Contract Research Organisations.....	89
12.2.1 Case Study: Eli Lilly & Co.	89
12.3 Quids	91
12.3.1 Rationale.....	91
12.3.2 PharmaDeals Analysis	92

13

Impact of the Credit Crunch and Future Trends	93
13.1 Deal Distributions.....	93
13.2 Deal Value Distributions.....	94
13.3 2009 and Beyond.....	96

Figures

1	All Deals by Year.....	9	32	Technology Access Agreements by Year.....	46
2	Product Deals Breakdown.....	10	33	Technology Access Agreements by Development Phase	47
3	Preclinical Deal Values by Year	10	34	Technology Access Agreements by Technology	47
4	Total Deal Values	11	35	Technology Access Agreements by Territory ...	48
5	Top 25 Pharmaceutical Companies: Deals versus Sales.....	12	36	Technology Access Agreements by Deal Value	48
6	Deal Intensity of the Top 10 Pharmaceutical Companies.....	12	37	Technology Access Agreements by Therapeutic Area	49
7	Deal Intensity by Therapeutic Area.....	13	38	Total Co-Marketing & Co-Promotion Deals by Year.....	52
8	Deals by Territory.....	17	39	Co-Marketing & Co-Promotion Deals by Development Phase	53
9	Integrated Valuation Methods	20	40	Co-Marketing & Co-Promotion Deals by Technology	53
10	Hypothetical Deal Factors	21	41	Co-Marketing & Co-Promotion Deals by Territory	54
11	Pharmaceutical Product Decision Tree	22	42	Co-Marketing & Co-Promotion Deal Values ...	54
12	Approximate Deal Value Splits by Development Phase	23	43	Marketing Agreements by Year	59
13	All Licensing Deals By Year.....	26	44	Marketing Agreements by Development Phase	60
14	Simple Licensing Deals by Year	26	45	Marketing Agreements by Technology.....	60
15	Deal Values by Year	27	46	Marketing Agreements by Territory.....	61
16	Licensing Deals by Development Phase and Year	28	47	Marketing Agreements Total Deal Value	61
17	Licensing Deals by Technology	28	48	Marketing Agreements by Therapeutic Area..	62
18	Simple Licensing Deals by Technology.....	29	49	Product Acquisitions by Year.....	66
19	Territorial Distribution of Licensing Deals.....	29	50	Product Acquisitions by Development Phase ..	66
20	Simple Licensing Deals by Therapeutic Area...	30	51	Product Acquisitions by Technology	67
21	R&D Collaboration Deals	36	52	Product Acquisition by Territory	67
22	Collaborative R&D Deals by Development Phase	37	53	Product Acquisition Total Deal Values	68
23	Collaborative R&D Deals by Technology	37	54	Product Acquisition by Therapeutic Area.....	68
24	Collaborative R&D Deals by Territory.....	38	55	Option to Purchase Deals by Year	72
25	Collaborative R&D Deal Values	38	56	Option to Purchase Deal Values	72
26	Evaluation Agreements by Year	41	57	Option to Purchase Deals by Development Phase	73
27	Evaluation Agreements by Development Phase	42	58	Option to Purchase Deals by Technology.....	73
28	Evaluation Agreements by Technology.....	42	59	Option to Purchase Deals by Territory	74
29	Evaluation Agreements by Territory.....	42			
30	Evaluation Agreements by Value.....	43			
31	Evaluation Agreements by Therapeutic Area..	43			

60	Option to Purchase Deals by Therapeutic Area	75
61	Option to License Deals by Year.....	76
62	Option to License Deals by Development Phase	77
63	Option to License Deals by Technology	77
64	Option to License Deals by Territory	78
65	Option to License Deal Values.....	78
66	Option To License Deals by Therapeutic Area	79
67	Equity Investments – All Deals	84
68	Equity Investments by Development Phase.....	84
69	Equity Investment Deals by Technology.....	85
70	Equity Investment Deals by Territory.....	85
71	Equity Investments – Total Deal Values.....	86
72	Equity Investment Deals by Therapeutic Area	86
73	Distribution of Deal Types in 2007 and 2008	93
74	Distribution of Deal Types by Total Deal Value in 2007 and 2008	95
75	Average Value per Deal for 2007 and 2008 ...	96